Contents
Lipoprotein(a), usually written as Lp(a), is an inherited cholesterol-carrying particle that can increase the risk of atherosclerotic cardiovascular disease, heart attack, stroke, peripheral artery disease, and calcific aortic valve stenosis. Unlike LDL cholesterol and triglycerides, Lp(a) is determined primarily by your genes and usually changes very little in response to diet or exercise.
An elevated Lp(a) result does not mean that you currently have heart disease or that a cardiovascular event is inevitable. It means you have an important risk-enhancing factor that should be considered alongside LDL cholesterol, blood pressure, blood sugar, smoking history, family history, age, kidney health, inflammation, and any evidence of existing artery disease.
The 2026 ACC/AHA dyslipidemia guideline recommends measuring Lp(a) at least once during adulthood. Because Lp(a) is not included in a routine cholesterol panel, it generally must be ordered as a separate Lipoprotein(a) Test.
Ulta Lab Tests provides direct access to Lp(a) and related cardiovascular testing so patients can obtain objective information and discuss their results with a qualified healthcare provider. Laboratory testing provides health information but does not replace professional medical advice, diagnosis, or individualized treatment.
Lipoprotein(a) is a lipoprotein particle produced mainly by the liver. Structurally, it resembles an LDL particle but contains an additional protein called apolipoprotein(a) attached to its apolipoprotein B-100 component.
This extra protein gives Lp(a) characteristics that may contribute to:
Evidence from genetic, population, and prospective studies indicates that cardiovascular risk generally rises as Lp(a) concentration rises. Risk does not suddenly begin at one exact cutoff. The commonly used thresholds help healthcare providers identify levels that may meaningfully enhance a person’s overall risk.
LDL cholesterol, or LDL-C, reports how much cholesterol is carried within a group of LDL-related particles. Lp(a), by contrast, measures a specific inherited particle with an additional apolipoprotein(a) component.
A person can therefore have:
This is why a standard Lipid Panel Test may not reveal the complete cardiovascular-risk picture.
Elevated Lp(a) means that an inherited cardiovascular risk factor is present. It does not diagnose blocked arteries, heart disease, stroke, or aortic valve disease.
Current U.S. guidance considers an Lp(a) result of at least 125 nmol/L or 50 mg/dL a cardiovascular risk-enhancing factor. An Lp(a) concentration of approximately 250 nmol/L is associated with at least twice the long-term risk of heart attack or stroke compared with lower concentrations.
These are population-level estimates. Your personal risk depends on your complete health profile rather than Lp(a) alone.
Elevated Lp(a) may be especially important when it occurs with:
A high Lp(a) result does not mean you caused the problem through poor food choices, insufficient exercise, or another lifestyle behavior. Lp(a) concentration is determined primarily by inherited genetic variation.
It also does not mean healthy habits are unimportant. Diet, exercise, sleep, weight management, blood-pressure control, glucose management, and avoiding tobacco may not substantially lower Lp(a), but they can improve many of the other factors that determine your absolute cardiovascular risk.
Lp(a) can enter and remain within artery walls, where its cholesterol and oxidized phospholipids may contribute to inflammation and plaque formation. Over time, atherosclerotic plaque can narrow coronary arteries or become unstable, increasing the risk of a heart attack.
The same atherosclerotic process can affect arteries supplying the brain, legs, kidneys, and other organs. Elevated Lp(a) has been associated with ischemic stroke and peripheral artery disease as well as coronary artery disease.
Elevated Lp(a) is also associated with calcification and narrowing of the aortic valve. Aortic stenosis can eventually interfere with the heart’s ability to pump blood effectively.
An Lp(a) blood test does not diagnose valve disease. However, an elevated result may contribute useful information to a person’s lifetime cardiovascular-risk assessment.
High Lp(a) usually causes no direct symptoms. Symptoms generally appear only if associated cardiovascular or valve disease develops.
| Finding or risk factor | What it may suggest | Tests or evaluation that may provide more information |
|---|---|---|
| Family history of an early heart attack or stroke | Possible inherited cardiovascular risk | Lipoprotein(a) Test, Lipid Panel Test, and Apolipoprotein B Test |
| Known high Lp(a) in a parent, sibling, or child | Increased likelihood of a familial elevation | Lipoprotein(a) Test and a family-screening discussion |
| Familial hypercholesterolemia | Multiple inherited lipid-related risks may coexist | Lipoprotein(a) Test, Lipid Panel Test, and Apolipoprotein B Test |
| Heart attack or stroke despite apparently acceptable LDL cholesterol | Residual risk not fully reflected by LDL-C | Lipoprotein(a) Test, Apolipoprotein B Test, and hs-CRP Test |
| High LDL cholesterol or ApoB | Increased concentration or number of plaque-forming particles | Lipid Panel Test, Apolipoprotein B Test, and Lipoprotein(a) Test |
| Diabetes, chronic kidney disease, or hypertension | Higher baseline cardiovascular risk | Hemoglobin A1c Test, Glucose Test, Comprehensive Metabolic Panel, and Albumin Random Urine Test with Creatinine |
| Chest pressure, breathlessness, fainting, or reduced exercise tolerance | Possible heart or valve condition requiring clinical evaluation | Prompt medical assessment; laboratory testing alone is not sufficient |
| Sudden weakness, facial drooping, speech difficulty, or severe chest pain | Possible stroke or heart attack | Emergency medical care |
Safety note: Call emergency services for sudden chest pain, difficulty breathing, fainting, facial drooping, one-sided weakness, difficulty speaking, or other possible heart attack or stroke symptoms. Do not wait for outpatient laboratory testing.
The 2026 ACC/AHA dyslipidemia guideline recommends that all adults have Lp(a) measured at least once. Testing may be especially informative for people with:
Premature cardiovascular disease generally refers to disease occurring before age 55 in men or before age 65 in women. When elevated Lp(a) is identified, healthcare professionals may recommend testing first-degree relatives because family members may share the inherited risk.
Order the Lipoprotein(a) Test through Ulta Lab Tests.
The Lipoprotein(a) Test measures the concentration or mass of Lp(a) in a blood sample. It can identify an inherited risk factor that is not ordinarily reported on a standard Lipid Panel Test.
An Lp(a) result cannot show:
No single laboratory result should usually be interpreted in isolation. Your healthcare provider may consider blood pressure, symptoms, family history, existing health conditions, medications, other laboratory results, and cardiovascular imaging when appropriate.
| Lab test | What it measures | Why it may matter with elevated Lp(a) | Important limitation |
|---|---|---|---|
| Lipoprotein(a) Test | Concentration or mass of Lp(a) | Identifies inherited Lp(a)-related cardiovascular risk | Does not diagnose cardiovascular or aortic valve disease |
| Lipid Panel Test | Total cholesterol, LDL-C, HDL-C, and triglycerides | Assesses major modifiable lipid-related risk factors | Does not ordinarily include Lp(a) |
| Cardio IQ Apolipoprotein B Test | The number of ApoB-containing atherogenic particles | May better reflect particle burden, particularly in people with diabetes, high triglycerides, metabolic conditions, or cardiovascular disease | Does not replace assessment of Lp(a), blood pressure, glucose, or other risk factors |
| High-Sensitivity C-Reactive Protein Test | Low concentrations of C-reactive protein associated with systemic inflammation | May provide additional cardiovascular risk information in selected patients | It is nonspecific and may rise because of infection, injury, surgery, or inflammatory disease |
| Hemoglobin A1c Test | Average glucose exposure over approximately two to three months | Helps assess glucose regulation, prediabetes, and diabetes-related cardiovascular risk | May be affected by anemia, altered red blood cell survival, pregnancy, kidney disease, and some hemoglobin variants |
| Glucose Test | Blood glucose at the time of collection | Provides additional information about metabolic health | A single result may not represent long-term glucose control |
| Comprehensive Metabolic Panel Test | Glucose, electrolytes, liver-related biomarkers, proteins, and kidney-related measurements | Provides general metabolic, kidney, liver, and medication-monitoring context | Does not measure Lp(a), ApoB, or arterial plaque |
| TSH Test | Thyroid-stimulating hormone | Thyroid dysfunction can alter LDL cholesterol and other lipid measurements | An abnormal TSH result may require additional thyroid testing and clinical evaluation |
| Albumin Random Urine Test with Creatinine | Urine albumin relative to creatinine | May identify kidney damage associated with diabetes, hypertension, and increased cardiovascular risk | Results may be temporarily affected by exercise, infection, fever, dehydration, or menstruation |
Not everyone needs every cardiovascular test. A practical testing strategy should be based on the health question being investigated, previous results, personal risk factors, and guidance from a qualified healthcare provider.
For many adults who have never had Lp(a) measured, a reasonable starting combination is:
This combination identifies inherited Lp(a)-related risk while measuring LDL cholesterol, non-HDL cholesterol, HDL cholesterol, total cholesterol, and triglycerides.
Additional tests may be useful for people with diabetes, elevated triglycerides, established cardiovascular disease, metabolic risk, chronic inflammation, or uncertainty about residual cardiovascular risk:
A broader evaluation may be appropriate when there are additional symptoms, chronic conditions, medication considerations, kidney risk, or abnormal previous results. Depending on the situation, testing may include:
The purpose of additional testing is to answer specific health questions—not to order the largest possible panel.
Because Lp(a) is genetically determined and usually remains relatively stable, frequent repeat testing is generally unnecessary. A healthcare professional may consider repeating the Lipoprotein(a) Test when:
Modifiable biomarkers may require more regular monitoring. These may include results from a Lipid Panel Test, Apolipoprotein B Test, Hemoglobin A1c Test, Glucose Test, or kidney-function testing.
Lp(a) may be reported in nanomoles per liter, abbreviated nmol/L, or milligrams per deciliter, abbreviated mg/dL.
A fixed mathematical conversion between nmol/L and mg/dL is not reliable because apolipoprotein(a) particles differ in size among individuals. Interpret your result using the unit printed on your laboratory report rather than applying a general internet conversion formula.
| Reported result | General interpretation |
|---|---|
| Below 75 nmol/L or below 30 mg/dL | Generally considered a lower Lp(a)-related risk range |
| 75–124 nmol/L or 30–49 mg/dL | Intermediate range; overall cardiovascular-risk context matters |
| 125 nmol/L or higher, or 50 mg/dL or higher | Cardiovascular risk-enhancing level |
| Approximately 250 nmol/L | Associated with at least twice the long-term risk of heart attack or stroke compared with lower concentrations |
The values shown in different units are clinical reference points and should not be treated as exact mathematical conversions.
A result of 150 nmol/L may have a different practical meaning for:
This is why Lp(a) should be incorporated into a complete cardiovascular-risk assessment rather than interpreted as an isolated pass-or-fail number.
You may not be able to substantially change the inherited Lp(a) concentration, but many of the factors that determine your absolute cardiovascular risk can be evaluated and managed.
Review LDL-C, non-HDL-C, triglycerides, HDL-C, and total cholesterol with a Lipid Panel Test. An Apolipoprotein B Test may provide additional information about the total number of atherogenic particles.
Elevated Lp(a) may lead a healthcare professional to consider whether LDL-related risk should be addressed more intensively based on your complete clinical profile.
High blood pressure and diabetes can add to the strain on blood vessels. A Hemoglobin A1c Test and Glucose Test may help assess metabolic risk.
Kidney disease can increase cardiovascular risk. A Comprehensive Metabolic Panel Test includes creatinine and estimated kidney-function measurements, while an Albumin Random Urine Test with Creatinine may identify increased urinary albumin.
Tobacco damages blood vessels and substantially increases cardiovascular risk. Avoiding smoking and secondhand smoke remains important even though it will not directly lower Lp(a).
A dietary pattern emphasizing vegetables, fruits, legumes, whole grains, nuts, fish, unsaturated fats, and minimally processed foods can support LDL cholesterol, blood pressure, body weight, and glucose regulation.
Regular physical activity, healthy sleep, stress management, and weight management can also help improve overall cardiovascular health.
Because Lp(a) is inherited, parents, siblings, and children may benefit from discussing a Lipoprotein(a) Test with their healthcare professionals, particularly when the level is markedly elevated or the family has a history of premature cardiovascular disease.
Statins generally do not lower Lp(a) and may modestly increase the measured concentration in some people. However, statins can substantially reduce LDL-related cardiovascular risk when clinically indicated.
Do not start, stop, or change any medication because of an Lp(a) result without consulting the prescribing healthcare professional.
Lifestyle changes generally have little direct effect on the inherited Lp(a) concentration. However, improving LDL cholesterol, blood pressure, blood sugar, physical activity, smoking exposure, sleep, and body weight may lower overall cardiovascular risk.
Some medications prescribed for established cardiovascular or cholesterol-related indications may also produce modest reductions in Lp(a), but medication selection should be based on a complete clinical evaluation—not on the Lp(a) number alone.
Lipoprotein apheresis is a specialized procedure that filters LDL and Lp(a) particles from the blood. It may be considered in rare, carefully selected cases involving severe inherited lipid disorders or progressive cardiovascular disease.
Several therapies designed to directly reduce production of apolipoprotein(a), including RNA-targeted treatments, are being evaluated in cardiovascular-outcome trials. These therapies remain investigational unless and until they receive regulatory approval for a specific indication.
Ulta Lab Tests allows consumers to order many laboratory tests directly online where available. Patients can review transparent self-pay pricing before ordering and visit an established laboratory collection network for specimen collection.
Benefits include:
Direct access can be useful for people who want to learn their Lp(a) level, complete a broader cardiovascular-risk assessment, or track modifiable biomarkers over time.
Explore relevant tests:
Laboratory results should be interpreted within the context of your medical history, family history, symptoms, medications, and other cardiovascular risk factors.
An isolated Lipoprotein(a) Test generally does not require fasting. However, preparation requirements may differ when Lp(a) is ordered with triglycerides, glucose, insulin, or other tests.
Before visiting the laboratory:
Current U.S. guidance considers an Lp(a) level of 125 nmol/L or higher, or 50 mg/dL or higher, a cardiovascular risk-enhancing factor. Risk generally rises progressively with concentration. An Lp(a) concentration around 250 nmol/L is associated with at least twice the long-term risk of heart attack or stroke compared with lower concentrations, although overall risk depends on many additional factors.
No. Elevated Lp(a) is a risk factor, not a diagnosis. The Lipoprotein(a) Test cannot show whether plaque is present, whether an artery is narrowed, or whether the aortic valve is calcified. Your result should be interpreted with your symptoms, medical history, blood pressure, cholesterol, glucose, family history, and any clinical or imaging findings.
Yes. Lp(a) is not ordinarily included in a standard Lipid Panel Test, and its concentration is largely determined by genetics. A person may have an acceptable routine LDL cholesterol result while still having elevated Lp(a). That is one reason current guidance recommends at least one Lp(a) measurement for every adult.
Lifestyle changes generally have little direct effect on the inherited Lp(a) concentration. However, nutritious eating, physical activity, healthy sleep, weight management, and avoiding tobacco can improve LDL cholesterol, blood pressure, insulin sensitivity, and overall cardiovascular health. These improvements may reduce the total cardiovascular risk surrounding elevated Lp(a).
No supplement has been proven to safely lower Lp(a) and reduce cardiovascular events. Some products may alter a laboratory measurement without evidence that they improve outcomes, and supplements can cause side effects or interact with medications. Discuss supplements with a qualified healthcare professional rather than attempting to treat an elevated Lp(a) result independently.
Statins do not usually lower Lp(a) and may modestly increase the measured concentration in some people. This does not mean statins are harmful for someone with elevated Lp(a). When clinically indicated, statins reduce LDL cholesterol and cardiovascular-event risk. Medication decisions should be based on the complete risk profile and made with the prescribing clinician.
Elevated Lp(a) often runs in families. When a person has a high level—especially with premature cardiovascular disease or familial hypercholesterolemia—testing parents, siblings, and children may identify relatives who share the inherited risk. The appropriate age and timing for testing children should be discussed with a pediatric or cardiovascular healthcare professional.
Usually not. Lp(a) is largely inherited and remains relatively stable, so one measurement is sufficient for most adults. Retesting may be considered when the original result was obtained during pregnancy, acute inflammation, significant kidney or thyroid dysfunction, or when the laboratory method or reporting unit creates uncertainty.
A Lipid Panel Test is the usual foundation. An Apolipoprotein B Test can help estimate total atherogenic-particle burden. A Hemoglobin A1c Test and Glucose Test assess metabolic risk, while an hs-CRP Test may provide inflammation-related information. Kidney and thyroid tests may also be appropriate depending on your history.
Ulta Lab Tests offers direct online access to many laboratory tests where available, including the Lipoprotein(a) Test. Consumers can order testing online, visit an affiliated collection location, and receive results securely. Results should be discussed with a qualified healthcare professional, particularly when Lp(a) or other cardiovascular biomarkers are elevated.
No. ApoB is present on several types of potentially atherogenic particles, including LDL particles, triglyceride-rich remnant particles, and Lp(a). An Apolipoprotein B Test estimates the total number of these particles, while a Lipoprotein(a) Test measures the specific inherited Lp(a) particle. The tests provide related but different information.
Not every elevated result requires specialist care. A referral may be worth discussing when Lp(a) is markedly elevated, cardiovascular disease occurred at a young age, familial hypercholesterolemia is suspected, cardiovascular events continue despite treatment, or management decisions are complex. A preventive cardiologist or lipid specialist can integrate Lp(a) with your complete risk profile.
Elevated Lp(a) is an important inherited cardiovascular risk factor that may remain hidden on an ordinary cholesterol panel. Knowing your level can help explain why apparently normal routine cholesterol results do not always tell the complete story.
An elevated result does not mean that a heart attack, stroke, or valve problem is inevitable. It provides information that can help you and your healthcare provider evaluate LDL cholesterol, ApoB, blood pressure, blood sugar, kidney health, smoking exposure, family screening, and other modifiable risks more carefully.
You may not be able to change the genes that determine your Lp(a), but you can take control of the surrounding cardiovascular-risk factors.
Explore the Lipoprotein(a) Test from Ulta Lab Tests, consider related heart-health testing based on your needs, and review your results with a qualified healthcare professional.
Lipoprotein(a), or Lp(a), is a largely inherited LDL-like particle that can increase the risk of atherosclerotic cardiovascular disease and calcific aortic valve stenosis. Elevated Lp(a) is a cardiovascular risk factor—not a diagnosis—and must be measured with a separate blood test because it is not included in a standard lipid panel.
Related laboratory tests: Lipoprotein(a) Test, Lipid Panel Test, Apolipoprotein B Test, High-Sensitivity C-Reactive Protein Test, Hemoglobin A1c Test, Glucose Test, Comprehensive Metabolic Panel Test, TSH Test, and Albumin Random Urine Test with Creatinine.
How Ulta Lab Tests helps: Ulta Lab Tests provides direct online access to Lp(a) and related cardiovascular laboratory testing, with transparent self-pay pricing and secure online results.
Laboratory testing is informational and should be reviewed with a qualified healthcare professional. Test results do not diagnose cardiovascular disease or replace medical evaluation.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
